Oruka Therapeutics, Inc. balance sheet ORKA

Annual Quarterly

As of Jun 30, 2026, Oruka Therapeutics, Inc. had total assets of $1.1 billion and total liabilities of $24.8 million. Total assets were up 218.8% from a year earlier. Stockholders' equity was $1.1 billion. It held $1.1 billion in cash and investments against $2.5 million of total debt, net cash of $1.1 billion. The current ratio, current assets divided by current liabilities, was 38.51.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Assets
Cash	268 +310.5%	50 -40.7%	47 -23.8%	91 -77.8%	65 +96.5%	84 +132.8%	62 +64.5%	411 +967.6%
Short-term investments	605 +130.1%	339 +27.8%	290 -7.6%	258	263	266	314	—
Long-term investments	252 +993.2%	107 +347.2%	143 +688.9%	152	23	24	18	—
Cash and investments	1,126 +220.3%	496 +32.9%	480 +21.8%	501 +21.9%	351 +956.0%	373 +939.0%	394 +951.8%	411 +967.6%
Total current assets	885 +166.4%	395 +12.3%	344 -8.8%	355 -14.0%	332 +881.7%	352 +860.1%	377 +902.5%	413 +961.8%
Property and equipment, net	0 +58.0%	0 +100.0%	0 +77.8%	0 +58.1%	0 +4250.0%	0 +2171.4%	0 +1520.0%	0 +1130.8%
Total assets	1,139 +218.8%	504 +33.8%	489 +23.4%	509 +23.0%	357 +956.1%	377 +927.4%	396 +946.0%	414 +956.8%
Liabilities and equity
Total current liabilities	23 +89.7%	17 +41.9%	15 +17.9%	21 +16.2%	12 +852.8%	12 +641.5%	13 +1947.6%	18 +1718.4%
Total liabilities	25 +80.3%	18 +43.4%	17 +20.9%	22 +19.0%	14 +983.9%	12 +683.5%	14 +1540.7%	19 +1452.7%
Stockholders' equity	1,115 +224.3%	487 +33.4%	472 +23.5%	487 +42.2%	344 +1285.7%	365 +5266.8%	382 +932.5%	342 +801.7%
Debt
Lease liabilities	3 +9.5%	2 +90.8%	2 +99.6%	2 +93.5%	2 +9591.7%	1 +1872.9%	1 +245.7%	1 +228.2%
Total debt	3 +9.5%	2 +90.8%	2 +99.6%	2 +93.5%	2 +9591.7%	1 +1872.9%	1 +245.7%	1 +228.2%
Net cash	1,123 +221.7%	494 +32.8%	478 +21.6%	499 +21.7%	349 +949.7%	372 +937.8%	393 +957.2%	410 +973.4%
Ratios
Current ratio	38.51x	23.76x	22.37x	16.94x	27.42x	30.03x	28.89x	22.89x
Debt to equity	0.00x	0.00x	0.00x	0.00x	0.01x	0.00x	0.00x	0.00x
Return on equity	-11.92%	-23.89%	-22.34%	-20.88%	-36.26%	-28.16%	-21.90%	-17.24%
Return on assets	-11.66%	-23.04%	-21.58%	-19.96%	-34.86%	-27.24%	-21.14%	-14.26%
Book value per share	18.25	9.70	9.69	10.06	9.18	9.74	10.21	9.78

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ORKA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Menlo Park, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 907654
Former names: ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.